CAPTRUST Financial Advisors’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

CAPTRUST Financial Advisors’s Portfolio GERM Stock Details GERM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-11,761	Closed	-$274K	–	4347
2022 Q2	$274K	Sell	11,761 -1,154	-9%	-$27.5K	﹤0.01%	1479
2022 Q1	$353K	Sell	12,915 -4,846	-27%	-$136K	﹤0.01%	1340
2021 Q4	$633K	Hold	17,761	–	–	﹤0.01%	1009
2021 Q3	$728K	Buy	17,761 +100	+0.6%	+$4.22K	0.01%	874
2021 Q2	$707K	Buy	17,661 +9,510	+117%	+$355K	0.01%	853
2021 Q1	$289K	Buy	8,151 +6,698	+461%	+$251K	﹤0.01%	1249
2020 Q4	$45K	Buy	1,453 +1,148	+376%	+$34.9K	﹤0.01%	1882
2020 Q3	$8K	Buy	+305	New	+$8.97K	﹤0.01%	2387

Other funds holding GERM

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

CAPTRUST Financial Advisors's GERM Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q3 2022, closing a stake of 11,761 shares — an estimated $274K sold.

CAPTRUST Financial Advisors first reported a position in GERM in Q3 2020 and held it in 8 quarters. The position peaked at $728K in Q3 2021. 22 funds tracked by Wall St. Rank hold GERM as of Q3 2022.

CAPTRUST Financial Advisors reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q3 2022 after selling out during the quarter.
CAPTRUST Financial Advisors sold 11,761 Amplify Treatments, Testing and Advancements ETF shares in Q3 2022, an estimated $274K.
CAPTRUST Financial Advisors first reported a position in Amplify Treatments, Testing and Advancements ETF in Q3 2020 and held it in 8 quarters.
CAPTRUST Financial Advisors's Amplify Treatments, Testing and Advancements ETF position peaked at $728K in Q3 2021.
22 funds tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.